16th Mar 2023 16:00
LEI: 549300Q7EXQQH6KF7Z84
16 March 2023
RTW Venture Fund Limited
Director Declaration
In accordance with LR 9.6.14, RTW Venture Fund Limited (the "Company") announces that Paul Le Page, a non-executive director of the Company, has been appointed as an independent non-executive director of TwentyFour Income Fund Limited, an LSE-listed FTSE 250 income fund, with effect from 16 March 2023.
For Further Information:
RTW Investments, LP | +44 (0)20 7959 6361 |
Woody Stileman, Managing Director |
|
|
|
Buchanan | +44 (0)20 7466 5107 |
Charles Ryland |
|
Henry Wilson |
|
George Beale |
|
|
|
J.P. Morgan Cazenove | +44 (0)20 7742 4000 |
William Simmonds |
|
Jérémie Birnbaum |
|
James Bouverat (Sales) |
|
| |
BofA Securities | +44 (0) 20 7628 1000 |
Edward Peel |
|
Kieran Millar |
|
| |
Elysium Fund Management Limited | +44 (0) 14 8181 0100 |
Joanna Duquemin Nicolle, Chief Executive Officer |
|
Sadie Morrison, Managing Director |
|
|
|
Morgan Stanley Fund Services USA LLC | +1 (914) 225 8885 |
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more information.
Related Shares:
Rtw Biotech